Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China flag China · Delayed Price · Currency is CNY
54.00
-1.56 (-2.81%)
Nov 17, 2026, 3:04 PM CST

SHE:002653 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
6,0244,3543,6933,3352,9982,765
Other Revenue
33.6233.6228.619.9417.038.46
6,0584,3883,7213,3553,0152,773
Revenue Growth
41.87%17.91%10.92%11.27%8.72%-16.71%
Cost of Revenue
1,3771,2661,062971.25925.27946.88
Gross Profit
4,6813,1212,6602,3842,0901,826
Selling, General & Admin
2,2892,0901,7631,5211,4641,331
Research & Development
1,173804.29624.13516.67447.87431.4
Other Operating Expenses
-54.5728.428.613.9835.8226.28
Operating Expenses
3,4052,9222,3982,0521,9481,789
Operating Income
1,277199.62262.03331.58141.5737.6
Interest Expense
-27.77-32.53-37.84-42.28-50.91-27.16
Interest & Investment Income
27.7125.85140.7119.33235.41426.35
Currency Exchange Gain (Loss)
-1.08-1.080.76-0.060.97-0.17
Other Non Operating Income (Expenses)
16.732.35-1.81-0.631.13-1.1
EBT Excluding Unusual Items
1,292194.2363.84307.93328.16435.52
Gain (Loss) on Sale of Investments
-17.15-17.150.08-60.47--
Gain (Loss) on Sale of Assets
-20.1-22.2731.1-0.28-0-0.13
Asset Writedown
-75.97-11.36-83.19-13.02-0.84-0.62
Other Unusual Items
130.15130.15151.1268.3739.375.97
Pretax Income
1,309273.58462.95302.52366.61510.74
Income Tax Expense
5.6814.02-3.256.96-25.1-6.84
Earnings From Continuing Operations
1,304259.56466.2295.56391.71517.58
Minority Interest in Earnings
0.020.02-70.74-0.45-114.64-172.52
Net Income
1,304259.58395.46295.11277.07345.06
Net Income to Common
1,304259.58395.46295.11277.07345.06
Net Income Growth
276.63%-34.36%34.00%6.51%-19.70%-45.80%
Shares Outstanding (Basic)
1,1321,1291,1301,0931,0661,078
Shares Outstanding (Diluted)
1,1321,1291,1301,0931,0661,078
Shares Change
0.22%-0.11%3.37%2.57%-1.17%-0.07%
EPS (Basic)
1.150.230.350.270.260.32
EPS (Diluted)
1.150.230.350.270.260.32
EPS Growth
275.82%-34.29%29.63%3.85%-18.75%-45.76%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
1,093454.031.3958.57-605.62-667.14
Free Cash Flow Per Share
0.970.400.000.05-0.57-0.62
Dividend Per Share
0.7930.2670.4150.200-0.185
Dividend Growth
487.41%-35.66%107.50%---50.22%
Gross Margin
77.27%71.14%71.47%71.05%69.31%65.86%
Operating Margin
21.07%4.55%7.04%9.88%4.70%1.36%
Profit Margin
21.52%5.92%10.63%8.80%9.19%12.44%
Free Cash Flow Margin
18.04%10.35%0.04%1.75%-20.09%-24.06%
EBITDA
1,557462.44502.03544.25317.33183.93
EBITDA Margin
25.70%10.54%13.49%16.22%10.52%6.63%
D&A For EBITDA
279.94262.82240212.67175.76146.33
EBIT
1,277199.62262.03331.58141.5737.6
EBIT Margin
21.07%4.55%7.04%9.88%4.70%1.36%
Effective Tax Rate
0.43%5.12%-2.30%--
Revenue as Reported
6,0584,3883,7213,3553,0152,773
Advertising Expenses
-----3.74